Citizens reiterates Market Perform on Phreesia stock amid mixed feedback
Citizens maintained a Market Perform rating on Phreesia (PHR) after mixed industry feedback. The stock trades at $11.28, with potential upside according to InvestingPro. Q2 2027 revenue rose 10% YoY to $129.5M, beating estimates, but EPS missed. Analysts have varied outlooks on growth and profitability.
How this was made
The 30-second read
Why it matters
No new material information; the piece serves as a recap of already‑public results.
Market read
Limited relevance; primarily a reminder of prior earnings and analyst opinions.
What to watch
Potential upside from AccessOne expansion to smaller providers.
Background
The article summarizes Phreesia's Q2 earnings, analyst rating changes, and commentary on AccessOne.
Ticker impact
Recaps Phreesia's Q2 fiscal 2027 results and mixed analyst rating changes, offering no fresh catalyst.
likely modest pressure as market prices in the downgrade and revenue slowdown
No new data beyond previously released earnings; analysts' rating adjustments suggest limited upside.
Market effects
Healthcare technology sector sees no immediate shift.
U.S. market impact minimal.
Limited to investors tracking Phreesia.
Counterpoint
If investors discount the downgrade, the stock could rebound on the EBITDA beat.
Key entities
- CompanyPhreesia Inc.
Provider of patient intake and payment solutions.




